Clinical Report: Mirtazapine Cuts Meth Use in Phase 3 Trial

Overview

Mirtazapine significantly reduced methamphetamine use days compared to placebo in patients with moderate to severe methamphetamine use disorder. The phase 3 trial demonstrated a statistically significant decrease of 7 days in the mirtazapine group versus 4.8 days in the placebo group over 12 weeks.

Background

Methamphetamine use disorder is a significant public health issue, with limited treatment options available. Current guidelines emphasize psychosocial interventions, but there is growing interest in pharmacotherapy. Mirtazapine, an antidepressant, has shown potential in reducing methamphetamine use, warranting further investigation.

Data Highlights

Key Findings

• Mirtazapine reduced methamphetamine use by 7 days compared to 4.8 days in the placebo group, with statistical significance.
• Mean reduction across follow-up was 1.8 fewer days of use with mirtazapine, statistically significant.
• Adverse events were more common in the mirtazapine group, including drowsiness (47% vs 33%, p<0.05) and weight gain (10% vs 3%, p<0.05).
• Discontinuation due to adverse events occurred in 23% of mirtazapine patients versus 15% in placebo, statistically significant.
• Reductions in methamphetamine use were consistent across sex and depression status.
• No significant differences were observed in depression, insomnia, or quality of life measures.

Clinical Implications

Mirtazapine may be a viable option for reducing methamphetamine use in patients with moderate to severe use disorder, particularly in outpatient settings. Clinicians should monitor for adverse effects, such as drowsiness and weight gain, as they may be more prevalent with mirtazapine treatment.

Conclusion

The findings suggest that mirtazapine can facilitate reductions in methamphetamine use, although careful consideration of its side effects is necessary. Further research is needed to confirm these results and explore long-term outcomes, particularly regarding safety and efficacy.

References

1. McKetin R, et al., JAMA Psychiatry, 2023 -- Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial
2. ASAM, Stimulant Use Disorder Guideline, 2024 -- Current consensus and guidelines
3. Drugs - Real World Outcomes — Assessing the Increased Risk of Hip Fractures Associated with Mirtazapine Use During Antidepressant Switches or Combination Therapy
4. Intensive Care Medicine — Exploring the Efficacy of Methotrimeprazine in Managing Refractory Agitation Among Pediatric Patients
5. BMC Psychiatry (Springer) — Monotherapy with Aripiprazole in Bipolar Disorder Patients Experiencing Delayed Sleep-Wake Phase Syndrome: A Case Series Analysis
6. Frontiers in Psychiatry — A Proposed Regimen of Existing Medications Including DXM, CYP2D6-Inhibiting Antidepressants, Piracetam, and Glutamine for Ketamine-Class Antidepressant Effects
7. Stimulant Use Disorder Guideline
8. Bupropion and Naltrexone in Methamphetamine Use Disorder
9. Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial - PubMed